ALKS 7119

Drug Profile

ALKS 7119

Alternative Names: ALKS7119

Latest Information Update: 04 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alkermes plc
  • Class Antidepressants; Nootropics
  • Mechanism of Action NMDA receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Agitation

Most Recent Events

  • 01 Oct 2016 Discontinued - Phase-I for Agitation (In volunteers) in Netherlands, USA (PO) due to unfavourable tolerability results (Alkermes plc 10-K, February 2017)
  • 01 Oct 2016 Discontinued - Preclinical for Agitation in Ireland (PO) due to unfavourable tolerability results (Alkermes plc 10-K, February 2017)
  • 28 Apr 2016 Alkermes plans a phase I multiple ascending dose study in Agitation (In volunteers) (NTR5956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top